Recurrent amplification at 7q21.2 targets CDK6 gene in primary myxofibrosarcomas and identifies CDK6 overexpression as an independent adverse prognosticator

Annals of Surgical Oncology

Volumn 19, Issue 8, 2012, Pages 2716-2725

  Tsai, Jen Wei ^a   Li, Chien Feng ^b,c,d,e   Kao, Yu Chien ^f   Wang, Jun Wen ^g   Fang, Fu Min ^g   Wang, Yu Hui ^g,h   Wu, Wen Ren ^c   Wu, Li Ching ^b   Hsing, Chung Hsi ^b   Li, Shau Hsuan ^g   Yu, Shih Chen ^g   Lan, Jui ^g   Huang, Hsuan Ying ^g  

^a E DA HOSPITAL   (Taiwan)

^b CHI MEI MEDICAL CENTER   (Taiwan)

^c NATIONAL SUN YAT SEN UNIVERSITY   (Taiwan)

^d NATIONAL HEALTH RESEARCH INSTITUTES   (Taiwan)

^e SOUTHERN TAIWAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Taiwan)

^f TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^g CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

^h NATIONAL CHENG KUNG UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN DEPENDENT KINASE 6; SCATTER FACTOR RECEPTOR;

ADULT; AGED; ARTICLE; CANCER CLASSIFICATION; CANCER GRADING; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; CHROMOSOME 7Q; CONTROLLED STUDY; DISEASE SPECIFIC SURVIVAL; DNA EXTRACTION; FEMALE; FIBROSARCOMA; GENE DOSAGE; GENE LOCATION; HUMAN; HUMAN TISSUE; LASER MICRODISSECTION; MAJOR CLINICAL STUDY; MALE; METASTASIS FREE SURVIVAL; MYXOFIBROSARCOMA; PRIMARY TUMOR; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TISSUE MICROARRAY; TUMOR CELL; TUMOR LOCALIZATION; TUMOR VOLUME;

ADULT; AGED; AGED, 80 AND OVER; CHROMOSOMES, HUMAN, PAIR 7; CYCLIN-DEPENDENT KINASE 6; DNA, NEOPLASM; FEMALE; FIBROSARCOMA; FOLLOW-UP STUDIES; GENE AMPLIFICATION; HUMANS; IMMUNOENZYME TECHNIQUES; MALE; MIDDLE AGED; MYXOSARCOMA; NEOPLASM GRADING; NEOPLASM STAGING; PROGNOSIS; PROSPECTIVE STUDIES; REAL-TIME POLYMERASE CHAIN REACTION; SURVIVAL RATE; TISSUE ARRAY ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 84864992498     PISSN: 10689265     EISSN: 15344681     Source Type: Journal    
DOI: 10.1245/s10434-012-2317-3     Document Type: Article

References (38)

1. HY Huang P Lal J Qin MF Brennan CR Antonescu 2004 Low-grade myxofibrosarcoma: a clinicopathologic analysis of 49 cases treated at a single institution with simultaneous assessment of the efficacy of 3-tier and 4-tier grading systems Hum Pathol. 35 612 621 15138937 10.1016/j.humpath.2004.01.016
2. T Mentzel E Calonje C Wadden RS Camplejohn A Beham MA Smith, et al. 1996 Myxofibrosarcoma. Clinicopathologic analysis of 75 cases with emphasis on the low-grade variant Am J Surg Pathol. 20 391 405 8604805 10.1097/00000478- 199604000-00001 1:STN:280:DyaK287otlertQ%3D%3D
3. JF van Roggen ME McMenamin CD Fletcher 2001 Cellular myxoma of soft tissue: a clinicopathological study of 38 cases confirming indolent clinical behaviour Histopathology. 39 287 297 11532040 10.1046/j.1365-2559.2001.01209.x
4. SM Willems AB Mohseny C Balog R Sewrajsing IH Briaire-de Bruijn J Knijnenburg, et al. 2009 Cellular/intramuscular myxoma and grade I myxofibrosarcoma are characterized by distinct genetic alterations and specific composition of their extracellular matrix J Cell Mol Med. 13 1291 1301 19320777 10.1111/j.1582-4934.2009.00747.x 1:CAS:528:DC%2BD1MXhtFCku7bO
5. CN Lin SC Chou CF Li KB Tsai WC Chen CY Hsiung, et al. 2006 Prognostic factors of myxofibrosarcomas: implications of margin status, tumor necrosis, and mitotic rate on survival J Surg Oncol. 93 294 303 16496357 10.1002/jso.20425
6. SM Willems M Debiec-Rychter K Szuhai PC Hogendoorn R Sciot 2006 Local recurrence of myxofibrosarcoma is associated with increase in tumour grade and cytogenetic aberrations, suggesting a multistep tumour progression model Mod Pathol. 19 407 416 16415793 10.1038/modpathol.3800550
7. R Sanfilippo R Miceli F Grosso M Fiore E Puma E Pennacchioli, et al. 2011 Myxofibrosarcoma: prognostic factors and survival in a series of patients treated at a single institution Ann Surg Oncol. 18 720 725 20878245 10.1245/s10434-010-1341-4
8. J Barretina BS Taylor S Banerji AH Ramos M Lagos-Quintana PL Decarolis, et al. 2010 Subtype-specific genomic alterations define new targets for soft-tissue sarcoma therapy Nat Genet. 42 715 721 20601955 10.1038/ng.619 1:CAS:528:DC%2BC3cXotlWktLY%3D
9. JC Lee CF Li FM Fang JW Wang YM Jeng SC Yu, et al. 2010 Prognostic implication of MET overexpression in myxofibrosarcomas: an integrative array comparative genomic hybridization, real-time quantitative PCR, immunoblotting, and immunohistochemical analysis Mod Pathol. 23 1379 1392 20639860 10.1038/modpathol.2010.128 1:CAS:528:DC%2BC3cXht1emtLfO
10. AM Snijders N Nowak R Segraves S Blackwood N Brown J Conroy, et al. 2001 Assembly of microarrays for genome-wide measurement of DNA copy number Nat Genet. 29 263 264 11687795 10.1038/ng754 1:CAS:528:DC%2BD3MXotlWhsLs%3D
11. M Malumbres M Barbacid 2009 Cell cycle, CDKs and cancer: a changing paradigm Nat Rev Cancer. 9 153 166 19238148 10.1038/nrc2602 1:CAS:528: DC%2BD1MXit1ans78%3D
12. S Nagel E Leich H Quentmeier C Meyer M Kaufmann HG Drexler, et al. 2008 Amplification at 7q22 targets cyclin-dependent kinase 6 in T-cell lymphoma Leukemia. 22 387 392 17989712 10.1038/sj.leu.2405028 1:CAS:528: DC%2BD1cXhvVylt7c%3D
13. F Mendrzyk B Radlwimmer S Joos F Kokocinski A Benner DE Stange, et al. 2005 Genomic and protein expression profiling identifies CDK6 as novel independent prognostic marker in medulloblastoma J Clin Oncol. 23 8853 8862 16314645 10.1200/JCO.2005.02.8589 1:CAS:528:DC%2BD28XisFE%3D
14. A Ismail S Bandla M Reveiller L Toia Z Zhou WE Gooding, et al. 2011 Early G cyclin-dependent kinases as prognostic markers and potential therapeutic targets in esophageal adenocarcinoma Clin Cancer Res. 17 4513 4522 21593195 10.1158/1078-0432.CCR-11-0244 1:CAS:528:DC%2BC3MXos1Smtbw%3D
15. H van Dekken R van Marion KJ Vissers WC Hop WN Dinjens HW Tilanus, et al. 2008 Molecular dissection of the chromosome band 7q21 amplicon in gastroesophageal junction adenocarcinomas identifies cyclin-dependent kinase 6 at both genomic and protein expression levels Genes Chromosomes Cancer. 47 649 656 18438866 10.1002/gcc.20570
16. C Louis-Brennetot JM Coindre C Ferreira G Perot P Terrier A Aurias 2011 The CDKN2A/CDKN2B/CDK4/CCND1 pathway is pivotal in well-differentiated and dedifferentiated liposarcoma oncogenesis: an analysis of 104 tumors Genes Chromosomes Cancer. 50 896 907 21910158 10.1002/gcc.20909 1:CAS:528: DC%2BC3MXhtFCmu77J
17. N Sirvent JM Coindre G Maire I Hostein F Keslair L Guillou, et al. 2007 Detection of MDM2-CDK4 amplification by fluorescence in situ hybridization in 200 paraffin-embedded tumor samples: utility in diagnosing adipocytic lesions and comparison with immunohistochemistry and real-time PCR Am J Surg Pathol. 31 1476 1489 17895748 10.1097/PAS.0b013e3180581fff
18. L Guillou JM Coindre F Bonichon BB Nguyen P Terrier F Collin, et al. 1997 Comparative study of the National Cancer Institute and French Federation of Cancer Centers Sarcoma Group grading systems in a population of 410 adult patients with soft tissue sarcoma J Clin Oncol. 15 350 362 8996162 1:STN:280:DyaK2s7kvFemtg%3D%3D
19. HY Huang CF Li FM Fang JW Tsai SH Li YT Lee, et al. 2010 Prognostic implication of ezrin overexpression in myxofibrosarcomas Ann Surg Oncol. 17 3212 3219 20585869 10.1245/s10434-010-1185-y
20. HY Huang SH Li SC Yu FF Chou CC Tzeng TH Hu, et al. 2009 Homozygous deletion of MTAP gene as a poor prognosticator in gastrointestinal stromal tumors Clin Cancer Res. 15 6963 6972 19887491 10.1158/1078-0432.CCR-09-1511 1:CAS:528:DC%2BD1MXhtl2ktLjN
21. HY Huang HY Kang CF Li HL Eng SC Chou CN Lin, et al. 2006 Skp2 overexpression is highly representative of intrinsic biological aggressiveness and independently associated with poor prognosis in primary localized myxofibrosarcomas Clin Cancer Res. 12 487 498 16428491 10.1158/1078-0432.CCR-05- 1497 1:CAS:528:DC%2BD28XmtlKitQ%3D%3D
22. F Dujardin MB Binh C Bouvier A Gomez-Brouchet F Larousserie A Muret, et al. 2011 MDM2 and CDK4 immunohistochemistry is a valuable tool in the differential diagnosis of low-grade osteosarcomas and other primary fibro-osseous lesions of the bone Mod Pathol. 24 624 637 21336260 10.1038/modpathol.2010.229 1:CAS:528:DC%2BC3MXlsVeqsLc%3D
23. MJ Grossel PW Hinds 2006 Beyond the cell cycle: a new role for Cdk6 in differentiation J Cell Biochem. 97 485 493 16294322 10.1002/jcb.20712 1:CAS:528:DC%2BD28Xht1Sqsb8%3D
24. JF Costello C Plass W Arap VM Chapman WA Held MS Berger, et al. 1997 Cyclin-dependent kinase 6 (CDK6) amplification in human gliomas identified using two-dimensional separation of genomic DNA Cancer Res. 57 1250 1254 9102208 1:STN:280:DyaK2s3jvVKqtQ%3D%3D
25. T Santarius J Shipley D Brewer MR Stratton CS Cooper 2010 A census of amplified and overexpressed human cancer genes Nat Rev Cancer. 10 59 64 20029424 10.1038/nrc2771 1:CAS:528:DC%2BD1MXhsF2hs7bF
26. V Brito-Babapulle AM Gruszka-Westwood G Platt CL Andersen MO Elnenaei E Matutes, et al. 2002 Translocation t(2;7)(p12;q21-22) with dysregulation of the CDK6 gene mapping to 7q21-22 in a non-Hodgkin's lymphoma with leukemia Haematologica. 87 357 362 11940479 1:CAS:528:DC%2BD38XjvFSrsr4%3D
27. F Cavazzini JA Hernandez A Gozzetti A Russo Rossi C De Angeli R Tiseo, et al. 2008 Chromosome 14q32 translocations involving the immunoglobulin heavy chain locus in chronic lymphocytic leukaemia identify a disease subset with poor prognosis Br J Haematol. 142 529 537 18547320 10.1111/j.1365-2141.2008.07227.x
28. XY Su M Busson V Della Valle P Ballerini N Dastugue P Talmant, et al. 2004 Various types of rearrangements target TLX3 locus in T-cell acute lymphoblastic leukemia Genes Chromosomes Cancer. 41 243 249 15334547 10.1002/gcc.20088 1:CAS:528:DC%2BD2cXptVemsrg%3D
29. K Kollmann G Heller RG Ott R Scheicher E Zebedin-Brandl C Schneckenleithner, et al. 2011 c-JUN promotes BCR-ABL-induced lymphoid leukemia by inhibiting methylation of the 5′ region of Cdk6 Blood. 117 4065 4075 21300982 10.1182/blood-2010-07-299644 1:CAS:528:DC%2BC3MXls1GhsLo%3D
30. G Toyokawa HS Cho Y Iwai M Yoshimatsu M Takawa S Hayami, et al. 2011 The histone demethylase JMJD2B plays an essential role in human carcinogenesis through positive regulation of cyclin-dependent kinase 6 Cancer Prev Res (Phila). 4 2051 2061 10.1158/1940-6207.CAPR-11-0290 1:CAS:528: DC%2BC38XhtV2ns7o%3D
31. X Agirre A Vilas-Zornoza A Jimenez-Velasco JI Martin-Subero L Cordeu L Gárate, et al. 2009 Epigenetic silencing of the tumor suppressor microRNA Hsa-miR-124a regulates CDK6 expression and confers a poor prognosis in acute lymphoblastic leukemia Cancer Res. 69 4443 4453 19435910 10.1158/0008-5472.CAN- 08-4025 1:CAS:528:DC%2BD1MXlvFWluro%3D
32. KH Lee C Lotterman C Karikari N Omura G Feldmann N Habbe, et al. 2009 Epigenetic silencing of MicroRNA miR-107 regulates cyclin-dependent kinase 6 expression in pancreatic cancer Pancreatology. 9 293 301 19407485 10.1159/000186051 1:CAS:528:DC%2BD1MXmtFCisL8%3D
33. F Sun H Fu Q Liu Y Tie J Zhu R Xing, et al. 2008 Downregulation of CCND1 and CDK6 by miR-34a induces cell cycle arrest FEBS Lett. 582 1564 1568 18406353 10.1016/j.febslet.2008.03.057 1:CAS:528:DC%2BD1cXkvVOhsrg%3D
34. Y Takahashi AR Forrest E Maeno T Hashimoto CO Daub J Yasuda 2009 MiR-107 and MiR-185 can induce cell cycle arrest in human non small cell lung cancer cell lines PLoS One. 4 e6677 19688090 10.1371/journal.pone.0006677
35. J Wu J Qian C Li L Kwok F Cheng P Liu, et al. 2010 miR-129 regulates cell proliferation by downregulating Cdk6 expression Cell Cycle. 9 1809 1818 20404570 10.4161/cc.9.9.11535 1:CAS:528:DC%2BC3cXht12itrvE
36. JJ Zhao J Lin T Lwin H Yang J Guo W Kong, et al. 2010 microRNA expression profile and identification of miR-29 as a prognostic marker and pathogenetic factor by targeting CDK6 in mantle cell lymphoma Blood. 115 2630 2639 20086245 10.1182/blood-2009-09-243147 1:CAS:528:DC%2BC3cXksFOhs7c%3D
37. Feng L, Xie Y, Zhang H, Wu Y. miR-107 targets cyclin-dependent kinase 6 expression, induces cell cycle G1 arrest and inhibits invasion in gastric cancer cells. Med Oncol. 2011. doi: 10.1007/s12032-12011-19823-12031 [Epub ahead of print].
38. LB Baughn M Di Liberto K Wu PL Toogood T Louie R Gottschalk, et al. 2006 A novel orally active small molecule potently induces G1 arrest in primary myeloma cells and prevents tumor growth by specific inhibition of cyclin-dependent kinase 4/6 Cancer Res. 66 7661 7667 16885367 10.1158/0008-5472.CAN-06-1098 1:CAS:528:DC%2BD28XnsFyru7s%3D